call it PCP - you might come across as a relic
call it PJP - you may seem cleverish
either way, don't call it PCP-pneumonia or PJP-pneumonia - you will come across as redundant redundant
this @idiots-pod.bsky.social is a great review of the clinical aspects of pneumocystis infections.
#idsky
Edinburgh is such a great place to live and work. Particularly in this sunny may.
Want to work here too (as a med micro +/- ID consultant)?
Well, check out this job advert: apply.jobs.scot.nhs.uk/Job/JobDetai...
< 72 h from launch → 48 placebo / active-controlled vaccine RCTs logged - now including all 5 COVID trials
1.43 M participants
Crowd-powered, freely accessible evidence that buries the “never placebo-tested” myth.
Browse or drop a PMID 👇
bit.ly/3EuYzqI
cc @bradspellberg.bsky.social
Two hospital 🇰🇷 retrospective cohort study of ID consult and CLABSIs in the ICU
ID consults associated with:
-faster catheter removal
-more targeted antimicrobials
bmcinfectdis.biomedcentral.com/articles/10....
#IDSky
Penicillin Susceptible Staphylococcus aureus IS REAL!
"this is all just part of my CPD record"
Seems like a good catchphrase
Dr Neil Stone talking about social media & medicine in Vienna at ESCMID Global.
Now it’s @drneilstone.bsky.social talking about social media and medicine. “Bluesky is the dominant platform now.”
He said it. We will get him over to Bluesky for good! 💪🏼😉😁
#ESCMIDGlobal
#IDSky #MedSky
Why is this not happening #ESCMID2025
Was looking for this content and couldn't find it. I'm newly covering maxfax and ENT areas - couldn't see that much content. Any recommendations on conferences for these?
An example of a commercially available system below.
Strikes me that locally we have all this data but due to different systems there is no way to view as overview and so need to spend time creating summaries.
Consequence of digitised systems rather than digital transformation of care?
Challenge of clinical decision support systems is the lag of legislation from technological change. Overarching challenge in many areas #escmidglobal
There was more covered. Great session!
5. Update on enterococcal breakpoints. Including other species
Remember intrinsic vanc resistance ones! Cassesiflavus and gallinarum
Update on upcoming new anaerobic breakpoints - exciting but methodology difficult and so likely ref lab still
4. Answers to questions about dosing: Generally to use breakpoints table. But in IE breakpoints refer to ESC guidelines. Also rationale for no I category and assumption that highest dose always used
This seems less useful (to me) given issues in ESC dosing tables and clinical data on oral switch.
3. Breakpoints for cefepime-enmetazobactam (always a pleasure to try to spell) and aztreonam-avibactam
2. Stenotrophomonas updated breakpoints:
Updates CoT R breakpoint. ECOFFS for other agents. And a nice bonus on mechanisms of beta lactams resistance
EUCAST updates #ESCMIDglobal
1. Strep pneumonia updated algorithm:
Use oxacillin disk, if >20mm then report A to all beta lactams. If <20mm read benpen 1 unit disk. Great presentation showing data behind and how well differentiates S/I/R
I'm now not so sure about HECK Yes. Patrick Harris was suggesting we should be more reluctant to switch from piptaz etc to mero based on risk of ampC unless Enterobacter.
Will be interesting to see next ESCMID DTR GN guidelines and IDSA 2025 on AmpC.
But for purposes of teaching, yes - HECK yes!
Interesting chart. Some doubt about oral beta lactams for bacteraemia oral switch given time/MIC concerns and not meeting PD target in Enterobacterales with higher MICs. Was this addressed at all? Perhaps need an organism/MIC specific approach?
This is a sensible bar for IVOS #ESCMID2025
It is so complex but Patrick Harris's talk key - clinical data (so far) shows mostly need to worry about Enterobacter CC. So I will watch with interest but likely not teach on till we have more clinical!
We talk about inducible AmpC and derepression of AmpC inducible, but what are the mechanisms?
Well, it's complex, but depends on the species. AmpR and PBP4 key players. I might need to watch this talk again.... (and easily can because the conference platform is excellent)! #escmidglobal
Useful summary of inducible AmpC - strength of inducement and susceptibility to hydrolysis #escmidglobal
Just gotten my head round the public transport and #escmidglobal is almost done! Having pre-paid travel has made it very easy!
It's fantastic that the replay feature is so smooth. Definitely watching this one on catch-up!
#AI is here + will become key in #antimicrobialstewardship #AMS
Flagged by Prof Thursky @ncas.bsky.social at #ESCMID2025 #ESCMIDGlobal - this paper is a great blueprint for implementing AI in AMS programmes
Link: www.thelancet.com/journals/lan...
Essential diagnostics in low-resource settings
Sipho Dlamini, Dissou Affolabi, @makedasemret.bsky.social insights on
💥 Brain drain
💥 Lack of granularity in calls to improve
💡 Lessons of networks (echoing TB labs) in SSA
Current status: www.thelancet.com/journals/lan...
#ESCMIDGlobal #ESCMID2025
If first within 72hrs and negative, repeat
Then repeat at 14/7 to decide whether to extend
Not a huge amount of studies so only 2/14 PICO questions had good data to answer.
My learning points from @runningmadprof.bsky.social
- continue aciclovir at 14/7 if CSF remains positive or if not improved
- when to test for aciclovir resistance: if not improving/deteriorating
- when to test for anti-NMDA ab: relapse/recurrence
- single plex > multiplex for HSV diagnosis
